UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 30, 2017

 

 IMMUNOMEDICS, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE   000-12104   61-1009366

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

300 The American Road, Morris Plains, New Jersey   07950
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (973) 605-8200

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 8.01. Other events

 

On January 30, 2017, Immunomedics, Inc. (the “Company”) issued a press release titled “Immunomedics Sets the Record Straight in New Presentation.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

 

Also on January 30, 2017, the Company posted on its website at www.immunomedics.com an investor presentation. In addition to being available on the Company’s website, a copy of the investor presentation is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01.

 

Item 9.01(d). Financial Statements and Exhibits.

 

Exhibit 99.1   Press Release of Immunomedics, Inc., dated January 30, 2017, titled “Immunomedics Sets the Record Straight in New Presentation”
Exhibit 99.2   Immunomedics, Inc. Investor Presentation, dated January 30, 2017

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUNOMEDICS, INC.
     
  By:

/s/ Michael R. Garone

Date: January 30, 2017   Name: Michael R. Garone
    Title: Vice President, Finance and Chief Financial Officer

 

 3 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
Exhibit 99.1   Press Release of Immunomedics, Inc., dated January 30, 2017, titled “Immunomedics Sets the Record Straight in New Presentation”
Exhibit 99.2   Immunomedics, Inc. Investor Presentation, dated January 30, 2017

 

 

4